Medical News

RSS

Strawberries may slow progression of precancerous lesions in the esophagus

Freeze-dried strawberries may be an alternative to drugs for the prevention of esophageal cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

6 Apr 2011

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen, Inc. announced today the launch of Inform™Thyroid, a panel of molecular markers used on Fine Needle Aspirates (FNA) of thyroid nodules to aid physicians in the management of thyroid cancer.

6 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

URAC awards specialty pharmacy and mail service pharmacy accreditation to BioScrip

BioScrip, Inc. announced today that it has been awarded specialty pharmacy and mail service pharmacy accreditation from URAC, a Washington, D.C.-based health care accrediting organization that establishes quality standards for the health care industry.

6 Apr 2011

Nu Skin first-quarter revenue increases 9% to $395 million

Nu Skin Enterprises, Inc. today announced that it expects to exceed previous company guidance by posting first-quarter revenue of approximately $395 million, a 9 percent improvement over the prior-year period. Revenue is expected to benefit approximately 5 percent due to foreign currency fluctuations.

6 Apr 2011

First Editon: April 6, 2011

Today's headlines include stories and analysis of how the Ryan budget plan would change Medicare, Medicaid and the shape of the federal government.

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

Viking expects record sales of $3.0 million for quarter ended March 31, 2011

Viking Systems, Inc., a leading worldwide developer, manufacturer and marketer of 3D and 2D visualization solutions for complex minimally invasive surgery, expects to report record sales for the quarter ended March 31, 2011 that will exceed $3.0 million, an increase of more than 50% compared with $1.9 million in revenue reported for last year's first quarter, and more than a 30% sequential increase over the fourth quarter of 2010.

6 Apr 2011

Japanese MHLW approves Spectranetics LLD lead locking device

Spectranetics Corporation today announced that the Japanese Ministry of Health, Labor and Welfare granted approval for the LLD lead locking device, which is used for the removal of pacemaker and defibrillator cardiac leads.

6 Apr 2011

CCF: New findings about diversity in American family life

For their annual conference, "Tipping Point? When Minority Families Become the Majority," the Council on Contemporary Families has collected some of the most important—though often under-reported—new findings about diversity in American family life.

6 Apr 2011

Americans concerned about thyroid cancer development from mammography

Some Americans have expressed concern, due to an erroneous media report, that the small amount of radiation a patient receives from a mammogram may significantly increase the likelihood of developing thyroid cancer. This concern simply is not supported in scientific literature.

6 Apr 2011

BioWa, OBT enter license agreement to advance ADCC programs

BioWa, Inc. and Oxford BioTherapeutics Ltd today announced that they have entered into a license agreement to provide OBT with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

6 Apr 2011

American Heart Association's Walking Paths app helps motivate people for healthy life

Finding a safe, free and centrally located walking path is now as easy as picking up the phone, thanks to a new smartphone application from the American Heart Association.

6 Apr 2011

BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011.

6 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

Sagent begins initial public offering of 5,000,000 shares of common stock

Sagent Pharmaceuticals, announced that it has commenced an initial public offering of 5,000,000 shares of common stock.

6 Apr 2011

MEDICREA reports €18.2 million annual sales for first quarter 2011

The MEDICREA Group listed on Alternext by NYSE Euronext Paris, a medical device company specialized in the development of innovative surgical technologies for the treatment of spinal disorders, is publishing its 2010 audited annual results approved by the Board of Directors held on March 31st, 2011, and its 2011 first quarter sales.

6 Apr 2011

FDA to discuss 2008 immunogenicity directives with European industry experts at Pharma IQ

This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's to discuss FDA directives on immunogenicity introduced in 2008.

6 Apr 2011

Only half of post-combat military service members having mental health issues seek treatment

Approximately 50 percent of military servicemembers returning from combat duty report experiencing a mental health issue, but only half of them have sought treatment. That is according to a recently released study titled Joining Forces America, a comprehensive survey of more than 1,000 military servicemembers, family members of servicemembers, and mental health professionals.

6 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011